Lisata Therapeutics, Inc.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of therapies for the treatment of solid tumors and other diseases. Its investigational product is certepetide, which is in Phase 2 clinical studies for the treatment of solid tumors, such as metastatic pancreatic ductal adenocarcinoma, cholangiocarcinoma, appendiceal cancer, and colon cancer and glioblastoma multiforme in combination with range of anti-cancer regimens. The company was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| RenTech | quant | 131.7K | $659.89K | 0.00% | Added+6.5% | 2026-03-31 |
| StateStreet | passive | 25.3K | $126.99K | 0.00% | Added+76.7% | 2026-03-31 |
| FidelityFMR | fundamental | 0 | $0 | 0.00% | Exited | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-06upcoming | — | — | — |
| 2025-11-06 | -0.53 | -0.49 | +8.41% |
| 2025-08-07 | -0.65 | -0.54 | +16.92% |
| 2025-05-08 | -0.53 | -0.55 | -3.77% |
| 2025-02-27 | -0.76 | -0.55 | +27.63% |
| 2024-11-12 | -0.75 | -0.59 | +21.33% |
| 2024-08-12 | -0.75 | -0.61 | +18.67% |
| 2024-05-09 | -0.72 | -0.65 | +10.34% |
| 2024-02-29 | -0.85 | -0.66 | +22.81% |
| 2023-11-02 | -0.93 | -0.65 | +30.11% |
| 2023-08-14 | -0.70 | -0.50 | +28.57% |
| 2023-05-09 | -0.81 | -0.77 | +4.94% |
| 2023-03-30 | -0.90 | -0.76 | +15.56% |
| 2022-11-10 | -1.27 | -1.47 | -15.49% |
| 2022-08-04 | -1.72 | -1.65 | +4.35% |
| 2022-05-05 | -1.72 | -1.05 | +39.13% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| LSTA | +3.83% | -24.59% | +74.73% | +24.52% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +0.86% | -19.96% | +78.17% | +11.83% |